DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ADVAIR HFA

Summary for Tradename: ADVAIR HFA

Patents:18
Applicants:1
NDAs:1
Suppliers: see list1
Formulation / Manufacturing:see details
drug
patent expirations by year for
 ADVAIR HFA

Clinical Trials for: ADVAIR HFA

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS
Status: Completed Condition: Asthma

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)
Status: Recruiting Condition: Asthma

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD
Status: Withdrawn Condition: Chronic Obstructive Pulmonary Disease; Sleep Disorders

Dose-Response of Salmeterol in Children
Status: Recruiting Condition: Asthma

The Effect on Depressive Symptoms in ECF Residents With COPD
Status: Completed Condition: Chronic Obstructive Pulmonary Disease; Depression

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair
Status: Completed Condition: Asthma

Atlantis Symbicort
Status: Completed Condition: Asthma

Effects of AdvairĀ® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation
Status: Completed Condition: Chronic Obstructive Pulmonary Disease (COPD)

Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep
Status: Not yet recruiting Condition: COPD

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
Status: Recruiting Condition: Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254Jun 8, 2006RXYes5,658,549*PED<disabled>Y<disabled>
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254Jun 8, 2006RXYes5,674,472*PED<disabled>Y<disabled>
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254Jun 8, 2006RXYes6,161,724*PED<disabled>Y<disabled>
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254Jun 8, 2006RXYes6,170,717*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc